Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies

Engineered red blood cells (RBCs) appear to be a promising method for therapeutic drug and protein delivery. With a number of agents in clinical trials (e.g., dexamethasone 21-phosphate in ataxia telangiectasia, asparaginase in pancreatic cancer/acute lymphoblastic leukemia, thymidine phosphorylase...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Luigia, Pierigè, Francesca, Aliano, Mattia Paolo, Magnani, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Leading Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211199/
https://www.ncbi.nlm.nih.gov/pubmed/32198632
http://dx.doi.org/10.1007/s40259-020-00415-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211199/
https://www.ncbi.nlm.nih.gov/pubmed/32198632
http://dx.doi.org/10.1007/s40259-020-00415-0

Ejemplares similares